Histologic classification of gliomas

Perry, Arie; Wesseling, Pieter

doi:10.1016/b978-0-12-802997-8.00005-0

Cited by 219 publications

(188 citation statements)

References 95 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…450k methylation data were downloaded directly from TCGA database. As oligodendroglioma has a different biology and prognosis than does astrocytoma, we excluded cases with chromosome 1p/19q deletion, which is a marker for oligodendroglioma (1). Data on the IDH mutation status were then obtained from the remaining cases using cBioportal, and cases were stratified into 2 groups on the basis of nonmutated WT (58 cases) or mutated (MUT; 150 cases) status in IDH1 or IDH2.…”

Section: Rt-pcrmentioning

confidence: 99%

“…Using level 3 gene expression data from TCGA database, we compared gene expression profiles of IDH-MUT (n = 149) and IDH-WT (n = 58) cases. As oligodendroglioma has a different biology and prognosis than does astrocytoma, we excluded cases with chromosome 1p/19q deletion, which is a marker for oligodendroglioma (1). Genes related to CD8 + CTLs (CD8A, CD8B, GZMA, and GZMB) (Figure 2A), IFN-γ and IFN-γ-inducible genes (IFNG and OAS2), as well as the chemokines CXCL9 and CXCL10 ( Figure 2B) were significantly lower in IDH-MUT cases compared with IDH-WT counterparts.…”

Section: Cd8mentioning

confidence: 99%

“…Grade IV glioblastomas (GBMs) are the most aggressive, with a median survival time of less than 15 months (2). While the majority of WHO grade I gliomas are curable, lowergrade (WHO grade II or III) diffuse gliomas (1) are considered malignant because of their invasive growth, resistance to therapy, and high risk of transforming into higher-grade gliomas (3).…”

Section: Introductionmentioning

confidence: 99%

“…Gliomas are the most common primary brain tumors and are typically classified on the basis of WHO criteria as grades I-IV, in order of increasing anaplasia (1). Grade IV glioblastomas (GBMs) are the most aggressive, with a median survival time of less than 15 months (2).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

Kohanbash¹,

Carrera²,

Shrivastav³

et al. 2017

Journal of Clinical Investigation

326

277

View full text Add to dashboard Cite

Section: Rt-pcrmentioning

confidence: 99%

Section: Cd8mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

Kohanbash¹,

Carrera²,

Shrivastav³

et al. 2017

Journal of Clinical Investigation

326

277

View full text Add to dashboard Cite

“…Furthermore, some morphology-based criteria were too vague for clinical practice, yielding tremendous interobserver variability and poor diagnostic reproducibility, even amongst expert consultants, the most egregious example being that of oligoastrocytoma [11]. Given the molecular advances in the last decade, it is, perhaps, not surprising that the greatest WHO modifications involved the diffuse gliomas and embryonal neoplasms.…”

mentioning

confidence: 99%

WHO’s arrived in 2016! An updated weather forecast for integrated brain tumor diagnosis

Perry

2016

Brain Tumor Pathol

Self Cite

View full text Add to dashboard Cite

A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis

et al. 2020

View full text Add to dashboard Cite

Despite much effort to improve treatments, patients with malignant glioma still present a very poor prognosis that has not changed significantly in the last decades. In this context, it is crucial to better understand glioma pathogenesis to identify new molecular prognostic subgroups and therapeutic targets. WNT6 was recently identified as a new oncogenic molecule in glioblastoma (GBM), with prognostic value in patients, but the mechanisms underlying WNT6 aberrant expression in glioma are still unknown. WNT6 was overexpressed in a subset of gliomas independently of IDH mutations, 1p/19q codeletion status, and WNT6 gene copy number. Interestingly, WNT6 expression is associated with the DNA methylation levels of particular CpG regions at both the WNT6 promoter and the gene body in glioma patient samples. HOXA9, a transcription factor previously associated with poorer clinical outcome in GBM, was identified as a novel transcriptional regulator of WNT6, activating the WNT/b-catenin pathway in vitro and in vivo. In various cohorts of glioma patients, mRNA levels of WNT6 and HOXA9 were significantly correlated, extending our in vitro and in vivo findings into the clinical setting. Interestingly, this novel molecular link between WNT6 and HOXA9 was not limited to glioma, as they were co-expressed also in patients with other tumor types. Clinically, WNT6 was a prognostic biomarker of shorter survival in GBM, independently of HOXA9 expression. Concomitant high expression of both WNT6 and HOXA9 identified a subgroup of patients with particularly dismal survival. These findings describe novel WNT6 regulatory mechanisms in GBM, establishing particular DNA methylation patterns and HOXA9 as critical regulators of WNT6 expression in glioma. This HOXA9-WNT6 molecular link supports WNT signaling in GBM cells and is a powerful Abbreviations 5-Aza, 5-aza-2'-deoxycytidine; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma

show abstract

Histologic classification of gliomas

Cited by 219 publications

References 95 publications

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

WHO’s arrived in 2016! An updated weather forecast for integrated brain tumor diagnosis

A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis

Contact Info

Product

Resources

About